Apellis announces new data from Phase 3 VALIANT study on EMPAVELI

Apellis (APLS) Pharmaceuticals announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robust and sustained efficacy of EMPAVELI, a C3 inhibitor, in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, IC-MPGN, rare and debilitating kidney diseases. Among seven EMPAVELI presentations at the upcoming American Society of Nephrology Kidney Week, the new results build on previous data showing durable reductions in proteinuria and stable kidney function over one year with EMPAVELI. New One-Year Phase 3 VALIANT Data Reinforce EMPAVELI’s Robust and Sustained Treatment Effect: Through one year, EMPAVELI sustained the significant 68% proteinuria reduction versus placebo achieved at Week 26, with consistent efficacy in patients who were or were not taking immunosuppressants and independent of baseline proteinuria levels. One-third of EMPAVELI-treated patients achieved complete proteinuria remission compared to 3% for placebo at week 26. These benefits were maintained through one year, and patients who switched from placebo experienced similar improvements